Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Top Headlines

Pharmaceutical Business Review

Bayer, Sprint Bioscience partner to develop new oncology drug candidates Bayer HealthCare has entered into a collaboration and license agreement with the Swedish company Sprint Bioscience to research, develop and commercialize oncology drug candidates. Contract Research & Services > Contract Research > News
FDA accepts OPKO’s NDA for rayaldee to treat CKD OPKO Health (OPK) announced that the US Food and Drug Administration (FDA) has accepted for review OPKO’s New Drug Application (NDA) for calcifediol modified-release capsules (proposed trade name, Rayaldee).
Regulatory Affairs > News Merck improves immuno-oncology portfolio with acquisition of cCAM Biotherapeutics Merck, known as MSD outside the United States and Canada, and cCAM Biotherapeutics announced that the companies have signed a definitive agreement under which Merck will acquire cCAM Biotherapeutics, a privately held biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies.
Production & Manufacturing > Manufacturing > News Regeneron, Sanofi launch new immuno-oncology collaboration Regeneron Pharmaceuticals and Sanofi have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology.
Contract Research & Services > Contract Services > News
EMA confirms successful validation of Teva's reslizumab MAA By PBR Staff Writer
Teva Pharmaceutical Industries has successfully filed a marketing authorization application (MAA) with the European Medicines Agency (EMA) seeking approval for reslizumab, a humanized anti-interleukin-5 (IL-5) monoclonal antibody (mAb).
Regulatory Affairs > News FDA grants breakthrough status for Progenics' Azedra to treat pheochromocytoma and paraganglioma By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Progenics Pharmaceuticals' Azedra to treat patients with iobenguane-avid metastatic or recurrent pheochromocytoma and paraganglioma.
Regulatory Affairs > News OncoMed begins Phase I trial of anti-RSPO3 antibody By PBR Staff Writer
OncoMed Pharmaceuticals has started dosing patients with advanced refractory solid tumors in its Phase Ia/Ib clinical trial of anti-RSPO3 antibody (OMP-131R10).
Contract Research & Services > Clinical Trials > News

Latest News and Insight by Sector

Production & Manufacturing

Merck improves immuno-oncology portfolio with acquisition of cCAM Biotherapeutics
Merck, known as MSD outside the United States and Canada, and cCAM Biotherapeutics announced that the companies have signed a definitive agreement under which Merck will acquire cCAM Biotherapeutics, a privately held biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies.
Production & Manufacturing > Manufacturing > News
Protecting Access to Pain Relief Coalition launches to ensure Americans have access to trusted pain relief
By PBR Staff Writer
The Protecting Access to Pain Relief (PAPR) Coalition officially launched to help ensure that American consumers continue to have access to, and choice of, safe and effective pain relief that is best suited to manage their condition.
Production & Manufacturing > OTC > News

Drug Research

DNDi, Takeda to develop new treatment for visceral leishmaniasis
By PBR Staff Writer
Switzerland-based Drugs for Neglected Diseases initiative (DNDi) and Takeda Pharmaceutical have signed an agreement to collaborate in the 'Lead Optimization Program' to discover the best compound among aminopyrazole series for developing a new treatment for visceral leishmaniasis (VL).
Drug Research > Drug Discovery & Development > News
China's Yabao and Lawson complete discovery validation work of annexin A5-based products
By PBR Staff Writer
China-based Yabao Pharmaceutical and Lawson Health Research Institute (Lawson) have completed the discovery validation work of products based on annexin A5 and moved the program into preclinical development.
Drug Research > Drug Discovery & Development > News

Inward Investment

PPF Group acquires minority stake in Cytune Pharma
By PBR Staff Writer
PPF Group, in cooperation with SOTIO has completed acquisition of minority stake in French biotechnology firm Cytune Pharma.
Inward Investment > News
Merck in talks to acquire Cubist Pharmaceuticals for nearly $8bn
By PBR Staff Writer
New Jersey-based drug giant Merck & Co is, reportedly, in talks over a potential acquisition of antibiotics maker Cubist Pharmaceuticals for more than $8bn.
Inward Investment > News

Packaging

Catalent completes acquisition of Australia's Pharmapak
By PBR Staff Writer
US-based Catalent Pharma Solutions has strengthened its ability to provide integrated solutions to customers with the acquisition of Pharmapak Technologies, an Australian pharmaceutical packaging business.
Production & Manufacturing > OTC > News
MP Global Products introduces foam-free packaging for shipment of temperature sensitive pharmaceuticals
MP Global Thermal Packaging Products insulated protective mailers and box liners are specifically designed for temperature control and protection of mail order shipments of temperature sensitive pharma, pet meds, and natural and organic cosmetics.
Packaging > News

Contract Research & Services

Regeneron, Sanofi launch new immuno-oncology collaboration
Regeneron Pharmaceuticals and Sanofi have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology.
Contract Research & Services > Contract Services > News
OncoMed begins Phase I trial of anti-RSPO3 antibody
By PBR Staff Writer
OncoMed Pharmaceuticals has started dosing patients with advanced refractory solid tumors in its Phase Ia/Ib clinical trial of anti-RSPO3 antibody (OMP-131R10).
Contract Research & Services > Clinical Trials > News

Automation

EyeGate gets USPTO notice of allowance for proprietary dexamethasone phosphate formulation
Eyegate Pharmaceuticals (EYEG), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, announced that it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent application related to its lead product candidate, EGP-437.
Automation > IT & Software > News
Pulmatrix issued patents covering iSPERSE technology to treat patients with inhaled dry powders
Pulmatrix (PULM) has been granted two patents from the US Patent and Trademark Office (U.S. Patent # 8,992,983 and US patent # 9,061,352), which cover the composition of matter for the company's underlying iSPERSE (inhaled Small Particles Easily Respirable and Emitted) inhaled dry powder technology as well as methods for treating a subject using respirable dry powders.
Automation > IT & Software > News

Regulatory Affairs

FDA accepts OPKO’s NDA for rayaldee to treat CKD
OPKO Health (OPK) announced that the US Food and Drug Administration (FDA) has accepted for review OPKO’s New Drug Application (NDA) for calcifediol modified-release capsules (proposed trade name, Rayaldee).
Regulatory Affairs > News
EMA confirms successful validation of Teva's reslizumab MAA
By PBR Staff Writer
Teva Pharmaceutical Industries has successfully filed a marketing authorization application (MAA) with the European Medicines Agency (EMA) seeking approval for reslizumab, a humanized anti-interleukin-5 (IL-5) monoclonal antibody (mAb).
Regulatory Affairs > News



Data-Label.co.uk DataLabel have been supplying
the medical industry with labels
for over 10 years

Manufactures of
healthcare packaging
machinery